Poor
Partially Aligned
Patient Risk:
Moderate
Summary
The AI claims broadly align with general labeling topics (indications, oral administration, and dose modifications), but the evaluation against the supplied FDA label excerpts cannot confirm support for most claims due to lack of an explicit mapping of each claim to specific provided label text. Several safety/administration details not covered by the excerpts are not verifiable, leading to low confidence alignment.
Category Scores
Accurate Statements
Rozlytrek is a cancer medicine whose active ingredient is entrectinib.
Supported by the provided label excerpts showing the product name ROZLYTREK (entrectinib).
Rozlytrek is used to treat certain types of tumors that have NTRK gene fusions.
Consistent with Section 1.2 NTRK gene fusion-positive solid tumors indication (as detected by an FDA-approved test, with clinical criteria).
Rozlytrek is used, in some cases, to treat ROS1-positive non-small cell lung cancer (NSCLC).
Consistent with Section 1.1 ROS1-positive metastatic NSCLC indication (adult patients, as detected by an FDA-approved test).
Rozlytrek is taken as an oral medication (tablet or capsule form, depending on the formulation in your market).
Supported that ROZLYTREK is administered orally and that available dosage forms include capsules, oral suspension, and oral pellets (Section 2.3/2.4). Note: label excerpt does not mention tablets.
Dosing for Rozlytrek may be adjusted for tolerability.
Consistent with Section 2.7 (dosage modifications for adverse reactions) and the concept of dose reduction/resumption based on severity (details provided in Section 2.7 and referenced Tables).
Unsupported Statements
Rozlytrek is prescribed for people with tumors that test positive for relevant targets such as NTRK gene fusions.
The label excerpt specifies additional selection criteria (metastatic or not amenable to surgery without severe morbidity; progressed or no satisfactory alternative therapy; and no known acquired resistance mutation for NTRK). The AI statement omits these required conditions and is therefore not fully supported by the provided excerpts.
Rozlytrek may be used in ROS1-positive NSCLC depending on the person’s disease characteristics and prior treatment history.
The provided ROS1 NSCLC excerpt states adult, ROS1-positive metastatic NSCLC as detected by an FDA-approved test, but does not include the specific phrasing about disease characteristics/prior treatment history in the excerpt. The AI statement is therefore not directly supported by the provided text.
Entrectinib is a targeted therapy that blocks signaling from oncogenic kinases driven by genetic rearrangements such as NTRK fusions.
No mechanism-of-action statement is present in the supplied label excerpts; therefore this is not supported by the provided prescribing information content.
Entrectinib blocks signaling from oncogenic kinases driven by genetic rearrangements such as ROS1.
No ROS1-related mechanism-of-action statement is present in the supplied label excerpts.
By blocking these pathways, entrectinib can slow tumor growth in cancers driven by those mutations.
No causal mechanism-to-outcome phrasing is provided in the supplied label excerpts.
Rozlytrek is marketed by Roche/Genentech.
No marketing/holder/manufacturer attribution is present in the supplied label excerpts.
Common side effects seen with entrectinib can include fatigue.
The provided label excerpt for adverse reactions only lists clinically significant adverse reactions (e.g., CHF, CNS effects, fractures, hepatotoxicity, hyperuricemia, QT prolongation, vision disorders) and does not list fatigue.
Common side effects seen with entrectinib can include dizziness.
The provided label excerpts do not list dizziness as a common side effect.
Common side effects seen with entrectinib can include gastrointestinal symptoms such as nausea and diarrhea.
The provided label excerpts do not list nausea/diarrhea as common side effects.
Common side effects seen with entrectinib can include changes in lab values.
While lab monitoring is mentioned for certain parameters (LVEF, uric acid, QT/electrolytes, liver tests), the excerpt does not state that 'common side effects' include general lab value changes.
The exact risk profile of entrectinib side effects depends on dose and the person’s underlying condition.
The provided excerpts support dose modifications and monitoring, but do not state this general relationship in the way claimed.
Dosing for Rozlytrek is based on the prescribing regimen.
The label states the physician should prescribe the most appropriate dosage form according to the dose required and patient needs (Section 2.3), but the specific phrasing 'based on the prescribing regimen' is not directly supported.
Contradictions
Important Omissions
For NTRK gene fusion-positive solid tumors, required selection criteria are omitted (metastatic or severe-morbidity surgery likelihood; progressed/no satisfactory alternative therapy; and no known acquired resistance mutation).
Importance:
Moderate
For ROS1-positive metastatic NSCLC, adult population requirement and that disease must be ROS1-positive metastatic NSCLC as detected by an FDA-approved test are not stated with required specificity.
Importance:
Moderate
Dose details and regimen specifics (e.g., 600 mg orally once daily for ROS1-positive NSCLC; Table-based pediatric/adult NTRK dosing) are not provided where dosing is discussed.
Importance:
Moderate
Key administration instructions from the label are omitted (e.g., capsules swallowed whole; suspension/enteral tube constraints; pellets sprinkled on soft food within 20 minutes; missed dose/vomiting instructions).
Importance:
Moderate
Key pre-treatment evaluation/monitoring instructions are omitted (LVEF, serum uric acid, QT interval and electrolytes).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Many claims are not supported by the supplied label excerpts (especially mechanism statements and 'common side effects'). The omission of label-required patient-selection criteria, dose specifics, and administration/monitoring instructions could lead to incomplete or inaccurate label-concordant interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims (mechanism, marketing attribution, and 'common side effects' list) are not supported by the provided label excerpts, and multiple label-specific eligibility criteria/administration/monitoring details are omitted.
Suggested Improvement
Limit statements to what is explicitly supported by the provided label excerpts: use label-accurate selection criteria for ROS1/NTRK indications, provide label dosing specifics (including the ROS1 600 mg once-daily regimen and Table-based NTRK dosing), and avoid asserting 'common side effects' not enumerated in the excerpts. Include key label administration and monitoring instructions when discussing use.